Avencell Europe Gmbh competitive analysis

Explore patent oppositions filed by Avencell Europe Gmbh against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating CancerUNIVERSITY OF MARYLANDJan 20, 2021

Latest PTAB cases involving Avencell Europe Gmbh

Discover the latest PTAB cases involving Avencell Europe Gmbh, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Avencell Europe Gmbh with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AVENCELL EUROPE GMBH1 - - -
UNIVERSITY OF MARYLAND - 5 - 2